The Anti-Portfolio Problem: What Your Fund’s Passes Say About Its Judgment

• Sahil Harwani
• August 6, 2026
• Blog
• #competewiser
• 0 Comments

The Anti-Portfolio Problem: What Your Fund’s Passes Say About Its Judgment

Every fund has an anti-portfolio – the deals it passed on that later became huge wins for someone else. Bessemer famously publishes theirs. Most funds never study their own, because reviewing a pass takes deliberate effort and reviewing a win doesn’t. That’s backwards: passes are the highest-signal dataset a fund has on its actual judgment, because wins can be partly luck, while a pattern of misses in the same category reveals a real, correctable bias.

Every partner has a version of this story, usually told with a wince: the deal that came through, that the fund passed on, that is now worth more than the entire fund.

Bessemer Venture Partners is famous for publishing this list on its own website – Facebook, Google, Airbnb, all passed on, all public, all still there for anyone to read. It’s a genuinely unusual act of institutional honesty. Most funds have an equivalent list. Almost none of them publish it. Fewer still actually study it internally.

The pattern behind the discomfort

Ask most partnerships how often they formally revisit their passes, and the honest answer is “rarely, and only when it’s already too painful not to.” Wins get a retrospective almost by default – there’s a portfolio review, an LP update, a war story at the partner offsite. Passes get discussed once, in the meeting where the deal died, and then the fund moves on. Nobody schedules a follow-up to check what happened to it.

That asymmetry isn’t laziness. It’s structural: a win is a scheduled event (a raise, an exit, a press release) that forces the fund to notice it. A pass has no such trigger. The company that got passed on doesn’t send a reminder when it raises its next round at 10x. The fund has to go looking, and almost nobody builds a system that goes looking automatically.

Why this stays invisible – even to disciplined partnerships

The instinct that stops most funds from doing this isn’t complacency, it’s a reasonable-sounding excuse: “we can’t know what would have happened if we’d said yes – hindsight bias makes every pass look worse than the decision actually was.” That’s true of any single pass, taken alone.

It stops being true the moment you look at passes in aggregate. One miss is noise. A pattern of misses – the fund consistently passing on a certain founder profile, a certain business model shape, a certain stage of traction – is not noise. That’s the fund’s actual risk model showing up in the data, whether or not any partner would describe their thesis that way out loud. Wins can be explained by luck, timing, or a market tailwind nobody predicted. A repeated category of misses is much harder to explain away, and that’s exactly why it’s worth more as a diagnostic.

What good actually looks like

The funds that treat their anti-portfolio as an asset rather than a wound tend to do three things differently:

• Log the reason for every pass, not just the decision. “Valuation” and “didn’t believe in the market” are different failure modes with different fixes; “passed” alone tells you nothing a year later.
• Revisit passes on a fixed schedule – a quarterly or annual pass-review, not only when a founder’s next round makes headlines and forces the conversation.
• Look for the pattern, not the individual case. The useful question isn’t “should we have said yes to this one deal” – it’s “what do our last thirty passes have in common, and is that a thesis or a blind spot.”

Where this actually breaks down operationally

Even partnerships that want to do this run into a mundane problem: the pass reasoning usually lives in someone’s head or a throwaway Slack message, not anywhere structured enough to review later. By the time it would be useful to look back, the context is gone – the analyst who ran that deal may not even be at the fund anymore.

This is a direct extension of the same institutional-brain problem we’ve written about before: a fund’s judgment shouldn’t live only in whichever partner remembers a specific deal. In CompeteWiser, every gated deal – passed or won – is logged with the stage it reached and the stated reason it stopped, structurally, not as a side note. Monitoring continues to track companies after a pass, the same way it tracks live portfolio companies, so “what happened to the ones we said no to” becomes a queryable pattern instead of an anecdote someone half-remembers at the partner offsite. Your anti-portfolio stops being a list you wince at and starts being the most honest audit of your own thesis that exists.

Curious what a structured review of your own fund’s passes might actually reveal? Email me at sahil@theprodzen.com.